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CCR5-tropic viruses cause the vast majority of new HIV-1 infections while about half of the individuals infected with HIV-1 manifest a co-
receptor switch (CCR5 (R5) to CXCR4 (X4)) prior to accelerated disease progression. The underlying biological mechanisms of X4 outgrowth in
AIDS patients are still poorly understood. Although X4 viruses have been associated with increased ‘‘virulence’’ in vivo, in vitro replication and
cytopathicity studies of X4 and R5 viruses have led to conflicting conclusions. We studied the replicative fitness of HIV-1 biological clones with
different co-receptor tropism, isolated from four AIDS patients. On average, R5 and X4 clones replicated equally well in mitogen-activated T cells.
In contrast, X4 variants were transferred more efficiently from dendritic cells to autologous CD4+ T cells. These observations suggest that
interaction between X4 viruses, DC and T cells might contribute to the preferential outgrowth of X4 viruses in AIDS patients.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; fitness; Replication capacity; CXCR4; CCR5; Dendritic cell; CD4+ T cell; Transmission; AIDSIntroduction
Infection of target cells by HIV-1 is mediated through high
affinity binding of the viral envelope to the human CD4
receptor and an additional co-receptor of the human chemokine
receptor family (CCR5 or CXCR4). Co-receptor use is
correlated with the ability of an isolate to induce syncytia in
the MT2 T-cell line (Asjo et al., 1986). Non-syncytium-
inducing (NSI) viruses use CCR5 (R5) and syncytium-
inducing (SI) variants use CXCR4 (X4) as entry co-receptor,
while dual tropic isolates can use both CCR5 and CXCR4
(R5X4) (Koning et al., 2002; Philpott, 2003). Differential co-
receptor usage (NSI/R5 and SI/X4) has been described for all
different HIV-1 clades (Zhang et al., 1996), although the
occurrence of SI/X4 variants in clade C viruses is rare (Abebe
et al., 1999; Peeters et al., 1999). It is understood that these
phenotypic properties are determined mainly by mutations in
the V2–V3 region of the HIV-1 env gene (Koning et al., 2002).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.11.045
* Corresponding author. Fax: +32 3 247 63 33.
E-mail address: karien@itg.be (K.K. Arie¨n).In vivo studies indicate that the vast majority of transmitted
HIV-1 is macrophage tropic, CCR5-using and non-syncytium
inducing (NSI/R5). (Asjo et al., 1986; van ’t Wout et al., 1994;
Zhu et al., 1993). Subjects with the CCR5D32 deletion lack a
functional CCR5 receptor and are resistant to HIV infection,
although in rare cases infection with SI/X4 virus has been
observed (Berger et al., 1999). Over the course of infection, the
co-receptor preference of HIV-1 changes from CCR5 to
CXCR4 in approximately 50% of infected individuals and
usually precedes an accelerated CD4+ T cell decline and
consequently disease progression (Tersmette et al., 1989; Koot
et al., 1993). Because only a limited number of mutations are
required for this phenotypic switch (Shimizu et al., 1999;
Verrier et al., 1999), it could be expected that X4 variants
evolve on multiple occasions throughout infection. HIV-1
biological or phenotypic properties such as co-receptor usage,
cell tropism, cytopathicity, and replication kinetics have been
extensively studied in vitro (Schuitemaker et al., 1991, 1992;
van ’t Wout et al., 1998; Grivel and Margolis, 1999; van Rij et
al., 2000; Kreisberg et al., 2001). However, the utilization of
diverse cellular systems and assays to measure phenotypic06) 65 – 74
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in current literature and the true biological mechanisms
underlying the ‘‘phenotypic switch’’ during HIV-1 infection
are still poorly understood.
In recent years, studies on HIV-1 replicative fitness have led
to new insights in the field of HIV/AIDS research (Quinones-
Mateu and Arts, 2001). Thus far, most research on HIV-1
fitness has established that primary drug resistance mutations
reduce replication capacity (Harrigan et al., 1998; Martinez-
Picado et al., 1999), while secondary or compensatory
mutations could increase fitness (Nijhuis et al., 1999). More
recent work has studied the impact of HIV-1 replicative fitness
on disease progression (Blaak et al., 1998; Quinones-Mateu et
al., 2000; Troyer et al., 2005, Arie¨n et al., 2005a), on the
evolution of the pandemic (Ball et al., 2003; Arie¨n et al.,
2005a, 2005b), and has also shown that entry/fusion is an
important determinant of HIV-1 fitness (Ball et al., 2003;
Rangel et al., 2003; Marozsan et al., 2005). We have recently
defined two parameters of ex vivo fitness: (1) Fpathogenic
fitness’ which measures the relative HIV-1 replicative fitness in
primary human T-cells, i.e., the major target cells during
chronic HIV-1 infection, and (2) Ftransmission fitness_ which
measures the efficiency of viral transfer from dendritic cells
(i.e., crucial targets during sexual HIV-1 transmission) to T-
cells (Blauvelt et al., 1997; Vanham et al., 2000a, 2000b; Ball
et al., 2003; Sivard et al., 2004; Arie¨n et al., 2005a, 2005b).
In this study, we have investigated the replicative fitness
of SI/X4 and NSI/R5 HIV-1 biological clones, isolated from
AIDS patients. In addition, we also determined the replica-
tion capacity of SI/X4 and NSI/R5 variants from the same
viral quasispecies, i.e., within a single patient. We performed
viral competition experiments employing human activated T-
cells and autologous co-cultures of dendritic cells and CD4+
T-cells.
Results
Characterization of SI/X4 and NSI/R5 HIV-1 biological clones
HIV-1 biological clones with distinct co-receptor tropism
were generated by limiting dilution (as described in detail by
Zhong et al., 1995) from each of four AIDS patients (CD4+ cell
count typically below 200 cells/Al blood; Fig. 1) and subjected
to head-to-head competitions in PHA/IL-2 activated PBMC
(i.e., activated T cells) and in autologous co-cultures of
dendritic cells and CD4+ T-cells (Fig. 2). Since antiretroviral
drug resistance mutations can influence HIV-1 replicative
fitness (Harrigan et al., 1998; Nijhuis et al., 1999), we
sequenced and analyzed the Pro-RT coding regions in the
Stanford University HIV drug resistance database. None of the
clones displayed any drug resistance mutations (data not
shown). In addition, sequences of the envelope gp120 coding
region were used for subtyping and determination of V3-loop
amino acid charge (Fig. 1B). Viruses VI 968 and VI 943
clustered with subtype B reference strains and VI 761 was
classified as subtype D. VI 820 clustered with subtype A and
CRF02_AG references (Fig. 1A). V3-loop amino acid chargeswere higher for X4 clones as compared to R5 clones for each
isolate, with differences in charge among clones with different
tropism varying from 3+ for VI 820 and VI 761, to 3+ and 2+
for VI 943, and to 2+ and 1+ for isolate VI 968 (Fig. 1B).
SI/X4 and NSI/R5 HIV-1 have comparable replicative fitness in
activated PBMC
SI/X4 and NSI/R5 HIV-1 clones from four AIDS patients
were competed against each other in mitogen-activated T-cells
(Fig. 2). When considering the replicative fitness between
clones from the same isolate, i.e., intra-isolate fitness (Fig. 3;
black bars), it was clear that among VI 943 clones, the VI 943-
1 (X4) clone was most fit (winning 6/6 competitions), followed
by clone VI 943-4 (R5) (winning 4/6), clone VI 943-2 (X4)
(winning 2/6) and finally clone VI 943-3 (R5) (losing all 6
competitions). Among the VI 968 clones, clone VI 968-1 (X4)
was the most fit (winning 6/6 competitions), followed by
clones VI 968-4 (X4) and VI 968-2 (R5) (both winning 2/6
competitions) and VI 968-3 (R5) was least fit (losing all 6
competitions). In the case of VI 761 and VI 820 clones, there
was only a single intra-isolate competition. The R5 clone of VI
761-1 out competed the X4 clone VI 761-4, while we obtained
no intra-isolate results on VI 820 clones, because we failed to
distinguish the R5 and X4 clones of this isolate in the
heteroduplex tracking assay.
A different picture was obtained in inter-isolate competi-
tions. All VI 943 clones were on average more fit than the R5
and X4 clones from the 3 other isolates in mitogen-activated
human T cells (winning 26/29 competitions), despite the clear
fitness differences amongst the VI 943 clones in intra-isolate
competitions (Fig. 3; gray bars). VI 968 and VI 761 isolates
harbored clones of intermediate replicative fitness, while both
clones of VI 820 were completely out competed by all clones
from other isolates (Fig. 3; gray bars). Clearly, in those cases
where biological clones were very fit or very unfit (VI 943 and
VI 820, respectively), the outcome of the competition was
independent of viral co-receptor use or syncytium-inducing
capacity.
SI/X4 HIV-1 clones are more efficiently transferred from
dendritic cells to T-cells
As a measure of viral transfer efficiency, we exposed
monocyte-derived dendritic cells to mixtures of equal infec-
tious doses of NSI/R5 and SI/X4 biological clones, washed
away excess virus and subsequently added autologous CD4+ T
cells, which were not pre-activated with PHA. When compet-
ing clones derived from the same patient isolate (i.e., intra-
isolate) (Fig. 4; black bars), the X4-clones appeared more fit
than the R5 clones from VI 943, VI 761 and VI 820. In
contrast, X4-clones VI 968-1 and VI 968-4 replicated less
efficiently in CD4+ T-cells after transfer from DCs (winning
only 2/6 competitions), compared to the R5-clones VI 968-2
and VI 968-3 (winning 4/6 competitions).
When competing isolates from different AIDS patients
against each other (i.e., inter-isolate) (Fig. 4; gray bars), all X4
Fig. 1. Virus characteristics. Twelve HIV-1 biological clones with distinct bio-phenotype, from four AIDS patients, were selected. VI 761 and VI 820 originate from
African patients. Env gp120 (partial) (Acc. No.: AM156911–AM156922) and Pro-RT were sequenced for subtyping and drug resistance analysis. (A) Phylogenetic
tree. Sequences determined in this study are in bold. A total of 1000 bootstrap samples were analyzed. Bootstrap values are given in percentages at the internodes if
they exceed the 70% level. The distance between two sequences is obtained by summing the lengths of the connecting branches by using the scale provided. The tree
is rooted arbitrarily. (B) V3-loop amino acid alignment. Positive V3-loop charge of amino acids in positions 11 and 25 (gray boxes) correlate with SI/X4 phenotype
for VI 943, VI 968, and VI 761. Viruses able to use the CXCR4 co-receptor have higher net V3-loop charges as compared to viruses that use CCR5. Arginine (R),
lysine (K), and histidine (H) are positively charged, while aspartic acid (D) and glutamic acid (E) are negatively charged.
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and 5). Nevertheless, VI 968, VI 761 and VI 820 R5-clones
were able to compete to some extent with the X4 clones, while
that was much less the case for VI 943. The R5-clones VI 943-3
and VI 943-4 lost all competitions against the other clones, both
X4 and R5, from AIDS patients (Fig. 4; gray bars).In summary, we found that HIV-1 biological clones of
distinct bio-phenotype and from different AIDS patients do not
display significant differences in replicative fitness in direct
competitions in activated PBMC (Fig. 5A, P > 0.05, t test). In
contrast, we showed that DCs can transfer both R5- and X4-
using HIV-1 variants to T-cells but that X4 HIV-1 variants
Fig. 2. Graphic representation of the experimental set up. (A) Dual infection/competition assay to measure relative viral fitness in diverse human cell types. Primary
human cell cultures are infected with two viruses at equal multiplicity of infection (MOI), and monoinfections correspond to positive controls. Excess virus is washed
away, culture medium is replaced every 3 days, and virus production is measured by p24 antigen detection. (B) Cells are harvested at peak p24 production, DNA is
extracted and part of the HIV-1 envgene is PCR amplified. Primers to PCR amplify competitions between clones from different patients (inter-competitions) are
spanning the C2V3-region, while a slightly larger region was amplified for competitions between clones of the same patients (intra-competitions). (C) Finally,
heteroduplex tracking assays (HTAs) employing radiolabeled probes were performed to quantify the amount of each virus after competition. Relative fitness values
(W) and a fitness ratio (WD) were derived as shown.
K.K. Arie¨n et al. / Virology 347 (2006) 65–7468seem to be more efficiently transferred from DCs to CD4+ T-
cells compared to R5 clones from the same or different HIV-1
quasispecies (Fig. 5B, P < 0.05, t test).
Entry as a determinant of HIV-1 fitness: impact of V3-loop
charge?
Previous studies have reported that HIV-1 replicative
fitness is primarily determined by the efficiency of primary
virus isolates to fuse to and enter host target cells (Ball et al.,
2003; Rangel et al., 2003; Marozsan et al., 2005). We found
that the V3-loop amino acid charge of X4 clones of VI 820,
VI 761, and VI 943 is on average 2.75+ higher then that ofFig. 3. Relative fitness of HIV-1 clones in human peripheral blood mononuclear ce
AIDS patients (VI 943, VI 968, VI 761, and VI 820), while panel B shows the mean
one virus clone against all other clones from the same HIV-1 isolate (i.e., intra-isola
from the other HIV-1 isolates (i.e., inter-isolate).R5 clones. In contrast, the difference in V3-loop charge of VI
968 R5 and X4 clones is only 1.5+ on average (Fig. 1B). The
R5 clones of VI 968 showed slightly higher V3-loop amino
acid charges (VI 968-2; 7+ and VI 968-3; 6+) compared to
the other R5 clones (VI 820-1; 3+, VI 761-1; 5+, VI 943-3;
5+, VI 943-4; 4+), and were in the range of V3-loop charges
observed for X4 HIV-1 clones (VI 820-4; 6+, VI 761-4; 8+,
VI 943-1; 7+, VI 943-2; 7+, VI 968-1; 8+, VI 968-4; 8+)
(Fig. 1B). Interestingly, VI 968 R5 clones also appeared to
replicate more efficiently in DC/T cell co-cultures compared
to R5 variants of other HIV-1 isolates. We speculate that the
increased V3-loop amino acid charge of VI 968 R5 viruses
may contribute to this fitness-advantage.lls (PBMC). Panel A shows the mean relative fitness of NSI/R5 clones of four
relative fitness of SI/X4 clones. Black bars represent the mean relative fitness of
te). Gray bars represent the mean relative fitness of one clone against all clones
Fig. 4. Relative fitness of HIV-1 clones in co-cultures of human dendritic cells and autologous CD4+ T cells. The mean relative fitness of NSI/R5 and SI/X4 clones
from AIDS patients is shown in panels A and B, respectively. Black bars represent the mean relative fitness of one virus clone against all other clones from the same
HIV-1 isolate (i.e., intra-isolate). Gray bars represent the mean relative fitness of one clone against all clones from the other HIV-1 isolates (i.e., inter-isolate).
K.K. Arie¨n et al. / Virology 347 (2006) 65–74 69Differential co-receptor expression on target cells may skew to
SI/X4 dominance
We have analyzed the expression of CCR5 and CXCR4 co-
receptors on gated CD4+ T cells (before and after PHA/IL-2
stimulation of PBMC), dendritic cells, and purified CD4+ T
cells (before and after 3 days of co-cultivation with DC) fromFig. 5. Average relative fitness of X4 and R5 HIV-1 biological clones. Panel A
depicts results from virus competitions in PBMC, while panel B shows results
in DC and CD4+ T cells. Direct competitions between diverse HIV-1 isolates in
PBMC show that the average fitness is close to 1 (i.e., no difference),
irrespective of the co-receptor use. SI/X4 clones appear to be slightly more fit
than NSI/CCR5 clones from the same isolate, although not significantly (P >
0.05, t test). In co-cultures of DC and T cells, the SI/X4 variants appear to be
more fit then NSI/R5 clones from the same or another isolate (P < 0.05, t test).three different HIV seronegative blood donors, by indirect
immunofluorescent staining and flow cytometry (Fig. 6). We
found that CXCR4 expression is higher than that of CCR5 both
on non-stimulated and PHA/IL-2 activated PBMC (Fig. 6).
PHA/IL-2 stimulation of PBMC results in up regulation of
CCR5 and down regulation of CXCR4, although the relative
expression of CXCR4 remains higher than that of CCR5 even
after activation with PHA and IL-2. As reported previously
(Vanham et al., 2000a, 2000b), the relative expression of CCR5
(Mean fluorescence intensity (MFI) = 81.3) on DC is higher
than that of CXCR4 (MFI = 16.5), while the opposite is seen
for purified CD4+ T cells (Fig. 6B). Interestingly, we found that
physiologic activation of CD4+ T cells by co-cultivation with
autologous DC, significantly up regulates the expression of
CXCR4 (MFI from 67.0 to 1008.1) and down regulates that of
CCR5 (MFI from 10.3 to 5.6) on the CD4+ T cell population
(Fig. 6B). Clearly, the ratio of relative CXCR4/CCR5
expression is much higher in DC-activated CD4+ T cells (i.e.,
180.0 in donor 3) as compared to PHA-activated CD4+ T cells
(5.4 in donor 1 and 11.2 in donor 2). In conclusion, mitogen-
activated PBMC and especially physiologically (i.e., by DC)
activated CD4+ T cells have higher CXCR4 expression relative
to CCR5, and may therefore be more permissive for SI/X4
HIV-1 variants.
Discussion
In this study we show that AIDS patients may harbor HIV-
1 viruses with different replicative fitness in human activated
T cells, regardless the viral co-receptor preference. When the
efficiency of virus transfer between DC and naı¨ve CD4+ T
cells was assessed, we found that X4 clones are more
efficiently transferred to T cells than R5 variants. This latter
observation is rather counterintuitive, because it is known that
CCR5-using viruses are causing the majority of new HIV-1
infections and dominate during the early stages of infection.
Immunofluorescent staining of various HIV-1 target cells (i.e.,
PBMC, DC, CD4+ T cells) revealed that CCR5 and CXCR4
are differentially expressed on the cell surface and may have
Fig. 6. CCR5 and CXCR4 co-receptor expression on the cell surface of PBMC,
DC and CD4+ T cells. Flow cytometry histograms (A) showing CCR5 and
CXCR4 expression on gated CD4+ T cells within PBMC (before and after
stimulation with PHA and IL-2), DC and CD4+ T cells (before and after
physiologic stimulation by DC). Panel B summarizes mean fluorescence
intensity (MFI) values for CCR5 and CXCR4 surface expression.
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variants.
It was generally accepted that macrophages and dendritic
cells are almost exclusively permissive for NSI/R5 strains and
there is substantial debate on whether macrophages and DCs
can sustain productive viral replication (Gendelman et al.,
1988; Schuitemaker et al., 1991; Schmidtmayerova et al., 1998,
Nobile et al., 2005). Tissue macrophages and also dendritic
cells in the mucosa of the reproductive organs are regarded as
selective portals of entry and constitute long-term viral
reservoirs (Orenstein et al., 1997). However, it was recently
reported that macrophages in human tonsil blocks (Jayakumaret al., 2005) and mucosal dendritic cells (Hlakdik et al., 1999;
Prakash et al., 2004, Nobile et al., 2005) could be productively
infected with CXCR4-using HIV-1 strains ex vivo. Although
we previously showed that productive infection of MO-DC is
largely restricted to R5 strains and clones (Vanham et al.,
2000a, 2000b), our present observations clearly demonstrate
that both R5 and X4 clones can be transferred from DCs to
autologous CD4+ T-cells, and that the transfer of X4 variants
appears to be even more efficient than that of R5 viruses. It has
been shown that DC-SIGN, a C-type lectin expressed on MO-
DC (and their physiological counterparts in the mucosa) can
capture and transfer both R5 and X4 viruses to CD4+ T cells.
During this process DC are not necessarily productively
infected, whereas the CD4+ T cells clearly are (Geijtenbeek
et al., 2000; Hlakdik et al., 1999).
If X4 viruses can be successfully transmitted/transferred,
why do they only appear in approximately 50% of HIV-1
infected individuals and usually only at later stages during
disease progression? Mucosal epithelial cells are known to
naturally secrete high levels of SDF-1a, the natural ligand of
CXCR4, and as a result, CXCR4 expression on mucosal T-cells
may be down regulated, rendering these cells less permissive
for X4 strains (Agace et al., 2000). However, R5 strains also
predominate in the early phases of parenteral infection (e.g.,
intravenous drug use), suggesting that other X4-restricting
barriers or R5-enhancing factors must exist (Cornelissen et al.,
1995; Harouse et al., 1999).
It is likely that R5 and X4 variants target different cell
populations upon infection (van Rij et al., 2000). Previous
studies reported that X4 strains preferentially target Fmemory_
CD4+ T cells, while R5 viruses may infect a subset of activated
mucosal T cells (Berger et al., 1999; van Rij et al., 2000,
Mattapallil et al., 2005; Li et al., 2005). Other studies using
human cervical tissue and monkey models have shown that
both activated and resting CD4+ T cells and not DC or LC are
the first cells infected by HIV-1 during transmission (Zhang et
al., 1999; Gupta et al., 2002). Our findings suggest that
CXCR4 is significantly up regulated by direct physiologic
stimulation from DC, as such advantaging the transfer of X4-
tropic HIV-1 variants. Interestingly, this observation suggests
that DC may play a less prominent role in transmission than
generally thought, and that local mucosal T cells (CCR5 rich)
could constitute the selective portal of entry.
In addition, different anatomical compartments have
different expression levels of CXCR4 and CCR5. There is
increasing evidence for a central role of the gut-associated
lymphoid tissue (GALT) in the replication of HIV-1 in vivo
(Veazey et al., 2001; Moore et al., 2004; Mattapallil et al.,
2005; Li et al., 2005). The GALT contains over half of the
human body’s total T-lymphocytes, and these cells tend to be
more activated than T cells in the peripheral blood. The
majority of GALT CD4+ T cells expresses CCR5 and has
inherently low CXCR4 expression (Veazey et al., 2000; Poles
et al., 2001). Another important site of viral replication is the
thymus, the major organ of naı¨ve T cell production, where
60–70% of the T cells express CXCR4 while CCR5
expression is marginally low (<5% of T cells) (Zamarchi et
K.K. Arie¨n et al. / Virology 347 (2006) 65–74 71al., 2002). The selective destruction of GALT Fmemory_
CD4+ T cells during primary HIV and SIV infection is a
continual but dynamic event, with the body making a valiant
effort to replace these cells (Mattapallil et al., 2005; Li et al.,
2005). It could be hypothesized that X4 variants may start to
dominate when the number of susceptible GALT-lymphocytes
has dropped below a critical level necessary for sustained R5
HIV-1 replication. Dendritic cells residing in the mucosa are
known to continuously traffic from the peripheral tissues to
the lymph nodes where they extensively interact with T cells,
which than re-circulate to blood and tissues. This physiolog-
ical process may play an important role in the distribution of
the R5-variants, but equally well in the outgrowth of late-
stage X4-variants.
In conclusion, we have shown that HIV-1 clones of both
bio-phenotypes are efficiently transferred from DCs to CD4+ T
cells, with X4 clones being remarkably superior in this respect.
Furthermore, our data suggest that the differential CCR5 and
CXCR4 co-receptor expression on HIV target cells may be an
important factor to favor X4 selection. Although our in vitro
observations do not provide a final answer to the reason for the
early dominance of R5 and late occurrence of an R5 to X4
Fswitch_ observed in only a proportion of the patients with
disease progression, they may have elucidated one of the




Four HIV-1 primary isolates were selected from our patient
cohort (ITM, Antwerp, Belgium) and twelve HIV-1 biological
clones (6 SI/CXCR4 (X4) and 6 NSI/CCR5 (R5)) were
generated by limiting dilution, as described in detail elsewhere
(Zhong et al., 1995). All virus isolates were obtained from
patients in advanced stage of disease (i.e., CD4+ cells <200
cells/Al, AIDS) (Fig. 1A). Co-receptor tropism and syncytium-
inducing capacity of all biological clones were determined on
U87.CD4 cells expressing either CCR5 or CXCR4 and on
MT2 T-cell lines, respectively. Virus stocks were generated by
short-term propagation of each biological clone in HIV-
seronegative donor PBMC. Afterwards, co-receptor tropism
was checked again using the U87-assay, to ensure that
biological clones had not evolved to dual receptor tropism
during the propagation process. Subsequently, tissue culture
dose for 50% infectivity (TCID50) was calculated using the
Reed and Muench method (Reed and Muench, 1938). Briefly,
each stock of HIV isolates was serially diluted and then plated
in 6-fold with 105 PBMC in a 96-well plate. Infectivity in each
well was tested using an in-house p24 antigen capture ELISA
(Beirnaert et al., 1998).
Cells
Peripheral blood mononuclear cells (PBMC) were obtained
from a HIV-seronegative buffy coat by Ficoll-Hypaque densitygradient centrifugation. PBMC were stimulated with 2 Ag/ml of
phytohemagglutinin (PHA) for 3 days and further maintained
in RPMI 1640—2 mM l-glutamine medium supplemented
with 10% fetal bovine serum (FBS), 10 mM HEPES, 1 ng/ml
interleukin-2 (IL-2), 100 U/ml penicillin and 100 Ag/ml
streptomycin. As described in detail previously (Vanham et
al., 2000a, 2000b), monocyte- and lymphocyte enriched
fractions were generated by counterflow elutriation of 6 
108 PBMC. Monocytes were further purified by sheep
erythrocyte rosetting, yielding >95% CD3 CD4+ monocytes
and <0.5% T cells. Addition of IL-4 (20 ng/ml) and GM-CSF
(20 ng/ml) to RPMI containing 10% FBS, 100 U/ml penicillin
and 100 Ag/ml streptomycin differentiates monocytes into
interstitial-type dendritic cells (MO-DC). Cell cultures were fed
every 3 days and immunophenotyped (CD3+/CD4+, CD1a+,
CD13+/CD14, DC-SIGN+) before use in infection experi-
ments on day 7. Frozen lymphocyte fractions were thawed on
the day of infection and used to isolate autologous CD4+ T
cells.
Immunofluorescent staining and flow cytometry
To assess the expression of CD4, CCR5 and CXCR4 on
CD4+ T-cells (before and after PHA/IL-2 stimulation of
PBMC), DC and purified CD4+ T cells (before and after co-
culture with DC), indirect immunofluorescent staining and
flow cytometry were used. Cells were washed once with
Dulbecco’s phosphate buffered saline (DPBS) (BioWhittaker
Cambex BioScience, Belgium), and resuspended in 50
Al DPBS containing 5% human serum (PBS 5% HuS) and,
1 Ag purified monoclonal antibody (mAb); anti-CD4, anti-
human CCR5 or CXCR4. 1 Ag IgG1 and IgG2a were used as
isotype matched control mAbs. After 20 min at 4 -C, cells
were washed with PBS containing 1% bovine serum albumin
(PBS/BSA/azide) and resuspended in 50 Al PBS 5% HuS and
1 Ag biotin-labeled goat anti-mouse. After incubating for 20
min at 4 -C, cells were washed once with PBS/BSA/azide and
resuspended in 50 Al 5% HuS and 1 Ag streptavidin-
phycoerythrin (PE). After 20 min at 4 -C, cells were washed
with PBS/BSA/azide and resuspended in 10 Al mouse serum.
After 10 min at 4 -C, FITC-conjugated mAb to CD4 was
added to the reaction. Subsequently, cells were washed with
PBS/BSA/azide and fixed with paraformaldehyde, after 20
min at 4 -C. The cells were analyzed on a FACScan (BD,
Belgium) to determine the level of surface CD4, CXCR4 and
CCR5 expression. The data were analyzed using WinMDI 2.8
software (http://facs.scripps.edu/software.html). mAbs to CD4,
CCR5 and CXCR4, biotinylated goat anti-mouse, FITC-
conjugated mAb to CD4, and streptavidin-PE conjugate were
obtained from BD PharMingen (San Jose, CA). Isotype
matched control Abs IgG1 and IgG2a were obtained from
Sigma-Aldrich (Saint Louis, Missouri USA).
Growth competition assays
Dual infections/competitions (Quinones-Mateu et al., 2000;
Ball et al., 2003; Troyer et al., 2005; Arie¨n et al., 2005a,
K.K. Arie¨n et al. / Virology 347 (2006) 65–74722005b) were performed with twelve biological clones of
distinct viral phenotype derived from four HIV-1 primary
patient isolates (Fig. 2). All dual infection/competition experi-
ments were performed with PHA/IL-2 activated PBMC from
one donor (same donor as for TCID50 determination and same
blood draw) on 24-well cell culture plates and in duplicate. A
sub-set of competitions was repeated in PBMC from one
additional donor to exclude host effects. Finally, the same
isolates were used in dual infections with MO-DC and
autologous Fresting_ CD4+ T-cells. Cells were infected with
two viruses at equal multiplicity of infection (0.0005 MOI for
PBMC and 0.001 MOI for MO-DC). Uninfected cultures were
used as HIV-negative controls and mono-infected cell cultures
of each virus correspond to positive controls. Virus mixtures
were incubated with 2  105 PBMC or 105 MO-DC at 37 -C
in 5% CO2 and washed three times with 1 phosphate-
buffered saline (PBS) 24 h post infection and then resuspended
in complete medium. Subsequently, 3  105 autologous CD4+
T-cells were added to the MO-DC and cultures were washed
and fed with complete medium twice a week. Cell-free
supernatant was assayed for p24 antigen detection 4 and 7
days post infection. Two aliquots of supernatants and cells
were harvested at day 10 after infection and stored at 80 -C
for subsequent analysis.
PCR strategy
For all dual infected and mono infected cultures, proviral
DNAwas extracted from lysed PBMC using the QIAamp DNA
Blood kit (Qiagen). Isolated viral DNA was PCR amplified
using a set of external primers (envB: 5V-AGAAAGAGCA-
GAAGACAGTGGCAATGA-3V and ED14: 5V-TCTTGCCTG-
GAGCTGTTTGATGCCCCAGAC-3V). Subsequently, nested
PCR amplicons (C2V3-region) were obtained using internal
primers E80 (5V-CCAATTCCCATACATTATTGTG-3V) and
E125 (5V-CAATTTCTGGGTCCCCTCCTGAGG-3V) for the
inter-isolate competitions, while a slightly larger, and in turn
more diverse, fragment (V3V5-region) was PCR amplified for
the intra-isolate competitions using internal primers ES7 (5V-
TGTAAAACGACGGCCAGTCTGTTAAATGGCAGTC-
TAGC-3V) and ES8 (5V-CAGGAAACAGCTATGACCCACTT-
CTCCAATTGTCCCTCA-3V). Both the external and nested
PCR reaction was carried out in a 100-Al reaction mixture under
defined cycling conditions (Fig. 2) (as described previously by
Quinones-Mateu et al., 2000; Ball et al., 2003; Troyer et al.,
2005; Arie¨n et al., 2005a, 2005b).
Heteroduplex tracking assay
Nested PCR products in env (C2-V3) were analyzed by
heteroduplex tracking assays (HTA) to determine the amount
of virus production in the dual infection/competition experi-
ments. Radiolabeled DNA probes were PCR amplified from
regions of env using the same primer sets described above. For
this amplification, one of the nested primers was radiolabeled
using T4 polynucleotide kinase and 2 ACi of [g-32P] ATP.
Subsequently, radiolabeled PCR-amplified probes were sepa-rated on 1% agarose gels and purified using the QIAquick gel
extraction kit (Qiagen). The HTA reaction mixtures contained
DNA annealing buffer (100 mM NaCl, 10 mM Tris–HCl [pH
7.8], 2 mM EDTA), 10 Al of amplified DNA from the
competition culture, and 0.1 pmol of radioactive probe DNA
were denatured at 95 -C for 3 min followed by incubation at 37
-C for 5 min and rapid transfer on wet ice to allow re-
annealing. The DNA heteroduplexes were resolved on 5% TBE
non-denaturing polyacrylamide gels (Bio-Rad) for 1h15 at 200
V. Afterwards, gels were dried for 45 min at 80 -C, exposed on
a phosphorimaging screen and scanned with a phosphor imager
(Cyclone, PerkinElmer) followed by analysis using the
OptiQuant software package from PerkinElmer (Fig. 2)
(described in detail elsewhere by Quinones-Mateu et al.,
2000; Ball et al., 2003; Troyer et al., 2005; Arie¨n et al.,
2005a, 2005b).
Estimation of viral fitness
In our dual infection/competition experiments, the final
ratio of two viruses produced in a dual infection was
estimated by heteroduplex tracking analysis and compared
to the production in monoinfections. Production of individual
HIV isolates in a dual infection ( fo) was divided by the initial
proportion in the inoculum (io). This is referred to as relative
fitness (W = fo/io), while the ratio of the relative fitness
values of each HIV variant in the competition is a measure of
the fitness difference (WD) or ratio between two HIV strains
(WD = WM/WL), with WM and WL corresponding to the
relative fitness of the more and less fit virus, respectively
(Fig. 2) (Quinones-Mateu et al., 2000).
Subtyping and sequence analyses
Pol fragments (nt 2280–3518) corresponding to protease
amino acid 10 through RT amino acid 323 were PCR
amplified using external primers PS1: 5V-TTTTTTAGG-
GAAAATTTGGCCTTC-3V and RTA9: 5V-TAAATTTAG-
GAGTCTTTCCCCATA-3V (1633 nt) and internal primers
PS2: 5V-TCCCTCAAATCACTCTTTGGCAAC-3V and RTA6-
subB: 5V-CCATTGGCCTTGCCCCTGCTTCTG-3V (1310 nt).
Nucleotide sequencing of pol (nt 2280–3518) and env
fragments (nt 688–1377) (Acc. No.: AM156911–AM156922)
was performed using an ABI 3730 DNA sequencer and ABI
PRISMBigDye Terminator cycle sequencing kits by the Genetic
Service Facility of the Flanders Interuniversity Institute for
Biotechnology (GSF-VIB). For phylogenetic subtyping analy-
ses, nucleotide sequences were aligned using ClustalX and then
manually edited for codon alignment. Alignments included a
representative set of known-subtype sequences recommended
by the Los Alamos National Laboratory HIV Sequence
Database. Distance calculation, tree construction, and boot-
strap analysis were realized with the software package
TREECON (Van de Peer and De Wachter, 1994). Drug
resistance analysis was performed using of the algorithms
available in the Stanford University Drug Resistance Database
(http://hivdb.stanford.edu/).
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